A detailed history of Canopy Partners, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Canopy Partners, LLC holds 4,380 shares of GILD stock, worth $411,501. This represents 0.16% of its overall portfolio holdings.

Number of Shares
4,380
Previous 4,495 2.56%
Holding current value
$411,501
Previous $308 Million 19.07%
% of portfolio
0.16%
Previous 0.14%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$66.59 - $83.99 $7,657 - $9,658
-115 Reduced 2.56%
4,380 $367 Million
Q2 2024

Aug 09, 2024

BUY
$63.15 - $72.88 $27,470 - $31,702
435 Added 10.71%
4,495 $308 Million
Q1 2024

May 15, 2024

BUY
$71.58 - $87.29 $28,130 - $34,304
393 Added 10.72%
4,060 $297 Million
Q4 2023

Feb 14, 2024

BUY
$73.27 - $83.09 $268,681 - $304,691
3,667 New
3,667 $297 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $118B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Canopy Partners, LLC Portfolio

Follow Canopy Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Canopy Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Canopy Partners, LLC with notifications on news.